Thrombosis in the young: Epidemiology and risk factors. A focus on venous thrombosis

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 1-6

  Rosendaal, Fritz R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; AGE; ARTERY THROMBOSIS; CHILD; CONFERENCE PAPER; DIABETES MELLITUS; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INFANT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OBESITY; ORAL DRUG ADMINISTRATION; PREGNANCY; PRESCHOOL CHILD; PRIORITY JOURNAL; PUERPERIUM; SCHOOL CHILD; SMOKING HABIT; THROMBOSIS; VEIN THROMBOSIS;

EID: 0030756898     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657492     Document Type: Conference Paper

References (55)

1. Nordstrøm M, Lindblad B, Bergqvist D, Kjellstrøm T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-160.
2. Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996; 27: 373-380.
3. SIG Zorginformatie, Landelijke Medische Registratie (LMR). (SIG Health Care Information, National Medical Registration). Tables on hospital admissions, 1992-1994. (address: maliebaan 50, P.O. Box 14066, 3508 SC Utrecht). Utrecht 1996.
4. Centraal bureau voor de Statistiek. Overledenen naar doodsoorzaak 1994 (serie Al): primaire doodsoorzaken (3-cijferlijst), Nederland. CBS. Voorburg 1996.
5. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited Thrombophilia: Part 1.Thromb Haemost 1996; 76: 651-662.
6. Hopkins PN, Williams RR. Identification and relative weight of cardiovascular risk factors. Cardiol Clin 1986; 4: 3-31.
7. Marmot MG, Poulter NR. Primary prevention of stroke. Lancet 1992; 339: 347.
8. Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thrombosis Research 1993; 71: 337-359.
9. Koster T, Rosendaal FR, Reitsma PH, Van der Velden PA, BriNt E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms: Leiden Thrombophilia Study (LETS). Thromb Haemost 1994; 71: 719-722.
10. Andrew M. David M, Adams M, Kaiser A, Anderson R, Barnard D, Bernstein M, Brisson L, Cairney B, DeSai D, Israels S, Jardine L, Massicote P, Silva M. Venous thromboembolic complications (VTE) in children: first anayses of the Canadian registry of VTE. Blood 1994; 83: 1251-1257.
11. Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics 1995; 96: 939-943.
12. Branson HE, Marble R, Katz J, Griffin JH. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn. Lancet 1983; ii: 1165-1168.
13. Mahasandana C, Suvatte V, Chuansumrit A, Marlar RA, Manco-Johnson MJ, Jacobson LJ, Hathaway WF. Homozygous protein S deficiency in an infant with purpura fulminans. J Pediatr 1990; 117: 750-753.
14. Hakten M, Deniz U, Ozbag G, Ulutin ON. Two cases of homozygous antithrombin III deficiency in a family with congenital deficiency of ATIII. In: Thrombosis and haemorrhagic disorders. Senzinger H, Vinazzer H (eds). Schmitt und Meyer GmbH. Wurzberg 1989 (pp 177-181).
15. David M, Andrew M. Venous thromboembolic complications in children. J Pediatr 1993; 123: 337-346.
16. Nuss R, Hays T, Maco-Johnson M. Childhood thrombosis. Pediatrics 1995; 96: 291-294.
17. Carson NAJ, Neill DW. Metabolic abnormalities detected in a survey of mentally backwards individuals in Northern Ireland. Arch Dis Child 1962; 37: 505-513.
18. Heijboer H, Brandjes DPM, Bhller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-151
19. Koster T, Rosendaal FR, Briët E, Van der Meer FJM, Colly LP, Trienekens PH, Poort SR, Vandenbroucke JP. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995; 85: 2756-2761.
20. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
21. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330:517-22.
22. Bertina RM, Koeleman RPC, Koster T, Rosendaal FR, Dirven RJ, Ronde H de, Van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
23. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-1508.
24. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-917.
25. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-155.
26. Den Heijer M, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-762.
27. Simioni P, Prandoni P, Burlina A, Tormene D, Sardella C, Ferrari V, Benedetti L, Girolami A. Hyperhomocysteinemia and deep-vein thrombosis: a case-control study. Thromb Haemost 1996; 76: 883-886.
28. Poort SR, Rosendaal FR, reitsma PH, Bertina RM. A common genetic variation in the 3-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
29. Rothman KJ. Modern Epidemiology. Little, Brown and Co. Boston 1986.
30. Jordan WM. Pulmonary embolism. Lancet 1961; ii: 1146-1147.
31. Stadel BV. Oral contraceptives and cardiovascular disease (first of two parts). N Engl J Med 1981; 305: 612-618.
32. Sartwell PhE, Stolley P. Oral contraceptives and cardiovascular disease. Epidemiol Rev 1982; 4: 95-109.
33. World Health Organization. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346: 1575-1582.
34. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457.
35. World Health Organization. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346: 1582-1588.
36. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differeing progestagen components. Lancet 1995; 346: 1589-1593.
37. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Bhller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives contining a third-generation progestagen. Lancet 1995; 346: 1593-1596.
38. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312: 83-88.
39. Rintelen C, Mannhalter C, Ireland H, Lane DA, Knobl P, Lechner K, Pabinger I. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematol 1996; 93: 487-490.
40. Pabinger I, Schneider B, and the GTH study group. Thrombotic risk of women with hereditary antithrombin III-, protein C and protein S-deficiency taking oral contraceptive medication. Thromb Haemost 1994; 71: 548-552.
41. Treffers PE, Huidekoper BL, Weenink GH, Kloosterman GJ. Epidemiological observations of thrombo-embolic disease during pregnancy and in the puerperium, in 56,022 women. Int J Gynaecol Obstet 1983; 21: 327-331.
42. Kierkegaard A. Incidence and diagnosis of deep vein thrombosis associated with preganancy. Acta Obstet Gynecol Scand 1983; 62: 239-243.
43. Koster T. Deep-vein thrombosis. A population-based case-control study: Leiden Thrombophilia Study. Thesis, Leiden 1995.
44. Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama MM. thrombosis and pregnancy in congenital deficiencies in ATIII, protein C or protein S: study of 78 women. thromb Haemost 1990; 63: 319-320.
45. De Stefano V, Leone G, Mastrangelo S, Tripodi A, Rodeghiero F, Castaman G, Barbui T, Finazzi G, Bizzi B, Mannucci PM. Thrombosis during pregnancy and surgery in pateints with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1995; 74: 793-794.
46. Friederich PW, Sanson BJ, Simioni P, Zanardi S, Huisman MV, Kindt I, Prandoni P, Buller HR, Girolami A, Prins MH. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996; 125: 955-960.
47. Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210-215.
48. Hirsch DR, Mikkola KM, Marks PW, Fox EA, Dorfman DM, Ewenstein BM, Goldhaber SZ. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J 1996; 131: 1145-1148.
49. Bokarewa MI, Bremme K, Blomback M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996; 92: 473-478.
50. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994; 14: 1080-1083.
51. Lensen RPM, Rosendaal FR, Koster T, Allaart CF, Vandenbroucke JP, Bertina RM. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood 1997 (in press).
52. Bovill EG, Bauer KA, Dickermann JD, Callas P, West B. The clinical spectrum of heterozygous protein C deficiency in a large New Englang kindred. Blood 1989; 73: 712-717
53. Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briët E. Increased risk of venous thrombosis in carriers of protein C deficiency defect. Lancet 1993; 341: 134-138.
54. Miletich J, Sherman L, Broze G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991-996.
55. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. APC-resistance as an additional risk factor for thrombosis in protein C deficient families. Blood 1994; 84: 1031-1035.